UPDRS, PDQ-39, and LEU at baseline and after 6 months of LCIG therapy Table 2: Baseline 6 months Change p-values 28.1 21.4 -24% <0.01 UPDRS II, off UPDRS II, 10.4 4.9 -53% <0.01 on UPDRS III, 50.1 42.1 -16% 0.058 off 21.7 11.6 -47% <0.05 UPDRS III, on UPDRS total, 49.6 23.8 -53% <0.01 on 70.6 35.4 -50% <0.05 PDQ-39 LEU, mg/day 1,307 2,256 +73% <0.05 Data are expressed as mean. The change is in percent of the mean. UPDRS, Unified Disease Parkinson’s Rating Scale; PDQ-39, Disease Questionnaire-39; LEU, Levodopa Equivalent Unit. Parkinson’s
Table 2: UPDRS, PDQ-39, and LEU at baseline and after 6 months of LCIG therapy Baseline 6 months Change p-values UPDRS II, off 28.1 21.4 -24% <0.01 UPDRS II, on 10.4 4.9 -53% <0.01 UPDRS III, off 50.1 42.1 -16% 0.058 UPDRS III, on 21.7 11.6 -47% <0.05 UPDRS total, on 49.6 23.8 -53% <0.01 PDQ-39 70.6 35.4 -50% <0.05 LEU, mg/day 1,307 2,256 +73% <0.05 Data are expressed as mean. The change is in percent of the mean. UPDRS, Unified Parkinson’s Disease Rating Scale; PDQ-39, Parkinson’s Disease Questionnaire-39; LEU, Levodopa Equivalent Unit.
18_141001_Timpka.docx